Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(258)
•••
Post by qwerty22on Nov 21, 2022 3:17pm
108 Views
Post# 35116514

Money men like peptides

Money men like peptides
With the clin­ic in sight, Greg Verdine's start­up bags $178M for new class of tar­get­ed ther­a­pies
by Amber Tong

ARCH Ven­ture Part­ners is buy­ing in­to Greg Ver­dine’s vi­sion for a world where no tar­gets are off-lim­its — with the goal of fi­nal­ly push­ing the first drug in­to the clin­ic.

The size of the Se­ries D fi­nanc­ing — $178 mil­lion — match­es the grand am­bi­tions Fog­Phar­ma has sketched out with its He­li­con com­pounds, a new class of polypep­tide drugs it says com­bines the cell-pen­e­trat­ing ca­pac­i­ty of small mol­e­cules with the tar­get-en­gag­ing tenac­i­ty of bi­o­log­ics.

The biotech is hop­ing to file an IND for FOG-001, a TCF-block­ing β-catenin in­hibitor, by mid-2023, a few months be­hind a Q4 2022 pro­jec­tion that Ver­dine of­fered up at the time of Fog's $107 mil­lion Se­ries C in spring 2021. It’s al­so lin­ing up a slate of pro­grams hit­ting can­cer tar­gets that have been out of reach by oth­er ap­proach­es: TEAD, NRAS, Pan-KRAS, ERG and Cy­clin E1

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities